Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-22
2011-03-22
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07910603
ABSTRACT:
Compounds of the formulaor a pharmaceutically acceptable salt thereof, whereinR1is aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl or alkyl, all optionally substituted;R2is H; or aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl or alkyl, all optionally substituted;R3is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, all optionally substituted;X is a bond, —(CH2)m—N(R7)—(CH2)n—, —(CH2)m—O—(CH2)n—, —(CH2)m—S—(CH2)n—, —C(O)—, —CH(OH)—, —C(O)N(R7)—, —C(O)N(R7)-alkylene or —N(R7)C(O)—;R7is H or alkyl; andm and n are each 0-6, provided that the sum of m and n is 0-6;or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions thereof, and the use of said compounds in the treatment of cough, pain, anxiety, asthma, depression, alcohol abuse, urinary incontinence and overactive bladder are disclosed.
REFERENCES:
patent: 6262066 (2001-07-01), Tulshian et al.
patent: 6451816 (2002-09-01), Biedermann et al.
patent: 6455527 (2002-09-01), Tulshian et al.
patent: 6716846 (2004-04-01), Tulshian et al.
patent: 6727254 (2004-04-01), Tulshian et al.
patent: 7094784 (2006-08-01), Tulshian et al.
patent: 7485650 (2009-02-01), Sawutz et al.
patent: 2003/0195185 (2003-10-01), Burnett et al.
patent: 2004/0067950 (2004-04-01), Tulshian et al.
patent: WO95/04742 (1995-02-01), None
patent: WO97/48397 (1997-12-01), None
patent: WO98/25924 (1998-06-01), None
patent: WO00/06545 (2000-02-01), None
patent: WO03/039469 (2003-05-01), None
Varty et al., The Journal of pharmacology and experimental therapeutics, 2008, vol. 326, No. 2, pp. 672-682.
Ciccocioppo et al., physiology & behavior, vol. 79 (2003), pp. 121-128.
Rouget et al., British journal of pharmacology, vol. 141, (2004), pp. 1077-1083.
Zambello et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32 (2008), pp. 651-661.
Mcleod et al., European journal of pharmacology, vol. 630 (2010), pp. 112-120.
Fu et al., brain research, vol. 1078 (2006), pp. 212-218.
International Search Report for International Application No. PCT/US2006/041925 dated Feb. 12, 2007.
McLeod, Robbie L., et al.; “Antitussive Effect of Nociceptin/Orphanin FQ in Experimental Cough Models”; Pulmonary Pharmacology & Therapeutics; 15:213-216 (2002).
Written Opinion for International Application No. PCT/US2006/041925 (Apr. 2008).
Ho Ginny D.
Tulshian Deen
Yang Shu-Wei
Andres Janet L
Banerjee Krishna G.
Meade Eric A.
Rahmani Niloofar
Schering Corporation
LandOfFree
3-monosubstituted tropane derivatives as nociceptin receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-monosubstituted tropane derivatives as nociceptin receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-monosubstituted tropane derivatives as nociceptin receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2662636